Streetbeat News

Products Services

META

MSFT

Citigroup analysts have reiterated their bullish stance on Meta Platforms Inc (META) and Microsoft Corp (MSFT). They believe Meta is gaining a larger share of the online advertising market, with ad loads reaching 19% QTD. They also expect to hear more about Meta's GenAI plans in late October. Microsoft's new updates across Windows, Surface, Designer, and Search, as well as the focus on Designer and potential CoPilot, are seen as intriguing. The analysts also see opportunities for greater advertiser engagement with Microsoft Shopping and M365 Chat.

Portfolio Pulse from Anusuya Lahiri

September 22, 2023 | 7:09 pm

MTCH

Tinder, a subsidiary of Match Group (MTCH), has introduced a new ultra-premium subscription tier, Tinder Select, for its most active users. The subscription costs $499 per month and offers features like exclusive search and matching. The plan is invite-only and is offered to less than 1% of Tinder's most active users.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 6:54 pm

NVO

WW

Blue Cross Blue Shield of Michigan and Blue Care Network will change the prior authorization approval criteria for commercial PPO and HMO plans for weight loss drugs, including Contrave, Generic Amphetamine Sulfate, Qsymia, Saxenda, Wegovy, and Xenical, starting October 1.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 6:40 pm

UTHR

United Therapeutics announced recent milestones for its heart and kidney xenotransplantation programs. The second UHeart recipient is recovering after a successful transplant and UThymoKidney demonstrated normal function during a 61-day study. Human xenotransplant clinical studies could begin in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 6:18 pm

IKNA

Wedbush has initiated coverage on Ikena Oncology Inc (NASDAQ:IKNA) with an Outperform rating and a price target of $11. The company's lead asset, IK-930, a selective inhibitor of the transcriptional enhanced associate domain (TEAD), is currently being evaluated in a Phase 1 monotherapy study. Another promising asset is IK-595, a RAS pathway inhibitor. IKNA shares are up 12.14% at $4.6650.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 6:16 pm

ENVB

The U.S. is nearing approval for the psychedelic drug MDMA following successful clinical trials. This development could potentially impact the stock of Enveric Biosciences (ENVB), a company involved in the development of novel therapeutic compounds.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 5:55 pm

SPY

Federal Reserve's Mary Daly stated that generative AI is currently small in the grand scheme of things. However, she noted that it has the potential to improve productivity, but could also be disruptive. It is still early to determine the full impact of generative AI.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 5:33 pm

U

Unity's Marc Whitten has apologized for the company's new Runtime Fee policy, which was announced without sufficient community feedback. The policy aims to support the game engine's development. Changes include keeping the Unity Personal plan free with no Runtime Fee, increasing the revenue cap from $100,000 to $200,000, and removing the 'Made with Unity' splash screen requirement. Games with less than $1 million in trailing 12-month revenue will not be subject to the fee. The policy will apply from 2024 onwards, and will not affect current projects unless they are upgraded to the new Unity version.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 5:12 pm

ATVI

Activision Blizzard's (NASDAQ:ATVI) 'Call of Duty: Modern Warfare III', developed by Sledgehammer Games, features a new element where players can use marijuana smoke as a finishing move. The game also includes imagery of cannabis and smoking figures on badges, banners, and character outfits. The game is set to release on consoles and PC on Nov. 10.

Portfolio Pulse from Franca Quarneti

September 22, 2023 | 5:09 pm

MSFT

Microsoft Corp. (NASDAQ:MSFT) and Paige, a digital pathology specialist, are partnering to develop the world's largest image-based AI model for cancer detection. The AI model will be designed using over 1 billion images from 500,000 pathology slides across various cancer categories. Paige's FullFocus viewing tool, the only AI tool to have received FDA approval for use in pathology, will be used as a supplementary tool for prostate cancer identification. However, it may take years before the AI model is commercially available due to potential regulatory challenges.

Portfolio Pulse from Chris Bibey

September 22, 2023 | 5:09 pm